[
  {
    "ts": null,
    "headline": "Assessing West Pharmaceutical Services (WST) Valuation After Earnings Beat Guidance And US$1b Buyback Announcement",
    "summary": "West Pharmaceutical Services (WST) is back in focus after reporting fourth quarter and full year 2025 results that topped expectations, issuing 2026 growth guidance, and unveiling a new US$1b share repurchase program. See our latest analysis for West Pharmaceutical Services. Despite the latest earnings beat, dividend declaration and new US$1b buyback plan, West Pharmaceutical Services’ recent momentum has cooled, with a 30 day share price return of 6.39% decline and a 1 year total shareholder...",
    "url": "https://finnhub.io/api/news?id=67fc12d01c855b0ef180a5b34d6a3af1a00fea7127f7dc55fe05da76de9ed9ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771445453,
      "headline": "Assessing West Pharmaceutical Services (WST) Valuation After Earnings Beat Guidance And US$1b Buyback Announcement",
      "id": 139139474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "WST",
      "source": "Yahoo",
      "summary": "West Pharmaceutical Services (WST) is back in focus after reporting fourth quarter and full year 2025 results that topped expectations, issuing 2026 growth guidance, and unveiling a new US$1b share repurchase program. See our latest analysis for West Pharmaceutical Services. Despite the latest earnings beat, dividend declaration and new US$1b buyback plan, West Pharmaceutical Services’ recent momentum has cooled, with a 30 day share price return of 6.39% decline and a 1 year total shareholder...",
      "url": "https://finnhub.io/api/news?id=67fc12d01c855b0ef180a5b34d6a3af1a00fea7127f7dc55fe05da76de9ed9ad"
    }
  }
]